BACKGROUND: Recessive forms of osteogenesis imperfecta (OI) may be caused by mutations in LEPRE1, encoding prolyl 3-hydroxylase-1 (P3H1) or in CRTAP, encoding cartilage associated protein. These proteins constitute together with cyclophilin B (CyPB) the prolyl 3-hydroxylation complex that hydroxylates the Pro986 residue in both the type I and type II collagen alpha1-chains. METHODS: We screened LEPRE1, CRTAP and PPIB (encoding CyPB) in a European/Middle Eastern cohort of 20 lethal/severe OI patients without a type I collagen mutation. RESULTS: Four novel homozygous and compound heterozygous mutations were identified in LEPRE1 in four probands. Two probands survived the neonatal period, including one patient who is the eldest reported patient (17 7/12 years) so far with P3H1 deficiency. At birth, clinical and radiologic features were hardly distinguishable from those in patients with autosomal dominant (AD) severe/lethal OI. Follow-up data reveal that the longer lived patients develop a severe osteochondrodysplasia that overlaps with, but has some distinctive features from, AD OI. A new splice site mutation was identified in two of the four probands, affecting only one of three LEPRE1 mRNA splice forms, detected in this study. The affected splice form encodes a 736 amino acid (AA) protein with a "KDEL" endoplasmic reticulum retention signal. While western blotting and immunocytochemical analysis of fibroblast cultures revealed absence of this P3H1 protein, mass spectrometry and SDS-urea-PAGE data showed severe reduction of alpha1(I)Pro986 3-hydroxylation and overmodification of type I (pro)collagen chains in skin fibroblasts of the patients. CONCLUSION: These findings suggest that the 3-hydroxylation function of P3H1 is restricted to the 736AA splice form.
BACKGROUND: Recessive forms of osteogenesis imperfecta (OI) may be caused by mutations in LEPRE1, encoding prolyl 3-hydroxylase-1 (P3H1) or in CRTAP, encoding cartilage associated protein. These proteins constitute together with cyclophilin B (CyPB) the prolyl 3-hydroxylation complex that hydroxylates the Pro986 residue in both the type I and type II collagen alpha1-chains. METHODS: We screened LEPRE1, CRTAP and PPIB (encoding CyPB) in a European/Middle Eastern cohort of 20 lethal/severe OI patients without a type I collagen mutation. RESULTS: Four novel homozygous and compound heterozygous mutations were identified in LEPRE1 in four probands. Two probands survived the neonatal period, including one patient who is the eldest reported patient (17 7/12 years) so far with P3H1 deficiency. At birth, clinical and radiologic features were hardly distinguishable from those in patients with autosomal dominant (AD) severe/lethal OI. Follow-up data reveal that the longer lived patients develop a severe osteochondrodysplasia that overlaps with, but has some distinctive features from, AD OI. A new splice site mutation was identified in two of the four probands, affecting only one of three LEPRE1 mRNA splice forms, detected in this study. The affected splice form encodes a 736 amino acid (AA) protein with a "KDEL" endoplasmic reticulum retention signal. While western blotting and immunocytochemical analysis of fibroblast cultures revealed absence of this P3H1 protein, mass spectrometry and SDS-urea-PAGE data showed severe reduction of alpha1(I)Pro986 3-hydroxylation and overmodification of type I (pro)collagen chains in skin fibroblasts of the patients. CONCLUSION: These findings suggest that the 3-hydroxylation function of P3H1 is restricted to the 736AA splice form.
Authors: M Valli; A M Barnes; A Gallanti; W A Cabral; S Viglio; M A Weis; E Makareeva; D Eyre; S Leikin; F Antoniazzi; J C Marini; M Mottes Journal: Clin Genet Date: 2011-10-19 Impact factor: 4.438
Authors: Shawna M Pyott; Ulrike Schwarze; Helena E Christiansen; Melanie G Pepin; Dru F Leistritz; Richard Dineen; Catharine Harris; Barbara K Burton; Brad Angle; Katherine Kim; Michael D Sussman; Maryann Weis; David R Eyre; David W Russell; Kevin J McCarthy; Robert D Steiner; Peter H Byers Journal: Hum Mol Genet Date: 2011-01-31 Impact factor: 6.150
Authors: Russell J Fernandes; Alex W Farnand; Geoffrey R Traeger; Mary Ann Weis; David R Eyre Journal: J Biol Chem Date: 2011-07-11 Impact factor: 5.157
Authors: Janice A Vranka; Elena Pokidysheva; Lauren Hayashi; Keith Zientek; Kazunori Mizuno; Yoshihiro Ishikawa; Kerry Maddox; Sara Tufa; Douglas R Keene; Robert Klein; Hans Peter Bächinger Journal: J Biol Chem Date: 2010-04-02 Impact factor: 5.157
Authors: Yang Li; Daniel Ho; Huan Meng; Tania R Chan; Bo An; Hanry Yu; Barbara Brodsky; Albert S Jun; S Michael Yu Journal: Bioconjug Chem Date: 2013-01-03 Impact factor: 4.774
Authors: Aileen M Barnes; Erin M Carter; Wayne A Cabral; MaryAnn Weis; Weizhong Chang; Elena Makareeva; Sergey Leikin; Charles N Rotimi; David R Eyre; Cathleen L Raggio; Joan C Marini Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Dustin Baldridge; Jennifer Lennington; MaryAnn Weis; Erica P Homan; Ming-Ming Jiang; Elda Munivez; Douglas R Keene; William R Hogue; Shawna Pyott; Peter H Byers; Deborah Krakow; Daniel H Cohn; David R Eyre; Brendan Lee; Roy Morello Journal: PLoS One Date: 2010-05-11 Impact factor: 3.240